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a b s t r a c t 
Background: Methylation of viral DNA has been proposed as a novel biomarker for triage of human pa- 
pillomavirus (HPV) positive women at screening. This systematic review and meta-analysis aims to assess 
how methylation levels change with disease severity and to determine diagnostic test accuracy (DTA) in 
detecting high-grade cervical intra-epithelial neoplasia (CIN). 
Methods: We performed searches in MEDLINE, EMBASE and CENTRAL from inception to October 2019. 
Studies were eligible if they explored HPV methylation levels in HPV positive women. Data were extracted 
in duplicate and requested from authors where necessary. Random-effects models and a bivariate mixed- 
effects binary regression model were applied to determine pooled effect estimates. 
Findings: 44 studies with 8819 high-risk HPV positive women were eligible. The pooled estimates for 
positive methylation rate in HPV16 L1 gene were higher for high-grade CIN ( ≥CIN2/high-grade squa- 
mous intra-epithelial lesion (HSIL) (95% conﬁdence interval (95%CI:72 ·7% (47 ·8–92 ·2))) vs. low-grade CIN 
( ≤CIN1/low-grade squamous intra-epithelial lesion (LSIL) (44 ·4% (95%CI:16 ·0–74 ·1))). Pooled difference 
in mean methylation level was signiﬁcantly higher in ≥CIN2/HSIL vs. ≤CIN1/LSIL for HPV16 L1 (11 ·3% 
(95%CI:6 ·5–16 ·1)). Pooled odds ratio of HPV16 L1 methylation was 5 ·5 (95%CI:3 ·5–8 ·5) for ≥CIN2/HSIL vs. 
≤CIN1/LSIL ( p < 0 ·0 0 01). HPV16 L1/L2 genes performed best in predicting CIN2 or worse (pooled sensi- 
tivity 77% (95%CI:63–87), speciﬁcity 64% (95%CI:55–71), area under the curve (0 ·73 (95%CI:0 ·69–0 ·77)). 
Interpretation: Higher HPV methylation is associated with increased disease severity, whilst HPV16 L1/L2 
genes demonstrated high diagnostic accuracy to detect high-grade CIN in HPV16 positive women. Di- 
rect clinical use is limited by the need for a multi-genotype and standardised assays. Next-generation 
multiplex HPV sequencing assays are under development and allow potential for rapid, automated and 
low-cost methylation testing. 
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2352-3964/© 2019 The Authors. Published by Elsevier B.V. This is an open access article u. Introduction 
Human papillomavirus (HPV) infects over 70% of sexually active
omen during their lifetime [1] . In most women, these infec-
ions are cleared whilst in a minority these persist and have theotential to lead to invasive cervical cancer [2] . Establishing that 
nder the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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Research in context 
Evidence before this study 
The results of studies exploring the use of methylation of 
viral DNA as a novel proposed biomarker in cervical cancer 
prevention have been encouraging. Variation in the explored 
HPV genotypes, genes and adjacent CpG sites across stud- 
ies together with differences in sequencing techniques and 
thresholds of positivity make comparisons and interpreta- 
tions diﬃcult. Although HPV methylation has been proposed 
as a possible candidate triage marker in HPV positive women 
at screening, the diagnostic accuracy of the test is not yet 
established. We aimed to determine how methylation levels 
change with cervical preinvasive disease grade and its diag- 
nostic accuracy in predicting high-grade cervical precancer 
in HPV positive women. Electronic bibliographic databases 
MEDLINE, EMBASE and CENTRAL from 1st January 1990 to 
1st October 2019 were searched for published studies, inves- 
tigating changes in methylation or diagnostic test accuracy, 
that reported the proportion methylation, mean (or median) 
methylation level, odds ratio or sensitivity, speciﬁcity or AUC. 
We used search terms including “Uterine Cervical Neoplasm”, 
“Cervical intraepithelial Neoplasia”, “Uterine Cervical Dyspla- 
sia”, “papillomaviradae”, “HPV”, “methylation”, “epigenetics”. 
There was no language restriction 
Added value of this study 
To date, this is the ﬁrst comprehensive systematic review 
and meta-analysis that explores the role of viral methyla- 
tion in cervical disease. We identiﬁed 44 studies and 8819 
women and included all HPV genotypes, genes and CpG loci. 
We found that positive methylation rate and mean methyla- 
tion increased with increasing disease severity for most genes 
with the most marked difference in the L1 and L2 region, 
with no difference in the LCR promoter/enhancer region. 
The pooled difference in mean methylation level was sig- 
niﬁcantly higher ≥CIN2/HSIL when compared to ≤CIN1/LSIL, 
and the difference was more marked for the HPV16 L1 gene 
(11 ·3%). HPV16 L1/L2 gene performed best in predicting CIN2 
or worse in HPV 16 positive women (pooled sensitivity 77%, 
speciﬁcity 64%, AUC 0 ·73). There were however limitations 
including substantial residual heterogeneity and the results 
should be interpreted with caution. The included studies 
used different test positive criteria, sequencing tests, tech- 
niques, and reference veriﬁcation standards. We performed a 
series of sensitivity analyses to reduce heterogeneity. 
Implications for all the available evidence 
This study suggests that HPV methylation may be a valuable 
epigenetic molecular determinant in cervical cancer preven- 
tion. The results summarise relative estimates for different 
HPV methylation sites, genes and combinations and inform 
the research community of the highest performing genes and 
sites that should be further explored in future studies. Stan- 
dardisation of threshold positivity and sequencing protocols 
is needed to allow valuable comparisons. The diagnostic ac- 
curacy of HPV16 L1/L2 in detecting high-grade CIN in HPV16 
positive women outperformed most available triage tests, al- 
though this was limited by the absence of a multiplex as- 
say that would include all hrHPV types. Such next-generation 
sequencing assays are being developed and have the poten- 
tial to allow rapid, automated and low-cost methylation test- 
ing. When available, clinical trials should perform head-to- 
head comparisons with other currently available triage tests 
in screening populations, to determine those women that 
warrant referral to colposcopy. The predictive value of viral 
methylation in infection and/or disease with true carcino- 
genic potential should also be explored in longitudinal co- 
horts. 
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s  ersistent infection with high-risk oncogenic HPV is causally asso-
iated with cervical cancer has led to major advances in cervical
ancer prevention. 
High-risk HPV (hrHPV) testing for primary cervical screening
ay offer 60–70% greater protection against invasive cancer than
ytology-based screening [3] . The estimated HPV prevalence in
creened populations varies from 9–15%, often reaching more than
0% in women aged less than 30 [4] , and in most cases infection
s transient. HPV testing has modest speciﬁcity and positive pre-
ictive value (PPV) for the detection of high-grade cervical intra-
pithelial neoplasia (CIN) [5] . The best strategy to triage HPV pos-
tive women at screening and detect those truly at risk remains
nclear. 
Novel molecular tests based on the HPV genome and
pigenome have the potential to permit a more comprehen-
ive understanding of the disease process and as a result improve
iagnostic accuracy within cervical screening programmes. DNA
yper-methylation is an early and frequent event in many cancers
nd methylation of viral DNA has been recently proposed as a
ovel biomarker of cervical disease. Rapid developments in se-
uencing technologies have enhanced scientiﬁc ability to explore
he HPV epigenome, together with its host interactions. Conse-
uently, the number of studies investigating the role of HPV DNA
ethylation in disease progression has increased in recent years,
he most comprehensive of which suggest an increase in methyla-
ion by disease grade in common high-risk HPV types [6–9] . 
Although results are encouraging [10] , variation in measure-
ent and reporting of methylation has made comparisons diﬃcult.
tudies examining genome-wide HPV methylation have thus far
een limited and methylation levels appear to vary by HPV geno-
ype, gene (L1, L2, E2-4, URR) and even amongst adjacent CpG sites
11 , 12] . Differences in case deﬁnitions and endpoints (e.g. cytology
s. histopathology, CIN2 vs. CIN3) further complicate comparisons
nd interpretation of the literature. To date, current evidence has
ot permitted analysis of the comparative performance of differ-
nt HPV methylation sites. To this end, we conducted a system-
tic review and meta-analysis of the existing literature with the
im to explore how methylation levels of different HPV genotypes
nd genes correlate with disease severity (CIN histological grade)
nd to further determine the diagnostic accuracy of HPV methy-
ation in detecting high-grade pre-invasive disease in HPV positive
omen. 
. Materials and methods 
.1. Selection criteria and search strategy 
The meta-analyses followed Preferred Reporting Items for Sys-
ematic Reviews and Meta-Analyses (PRISMA) guidelines and
ochrane Collaboration recommendations for diagnostic test accu-
acy reviews [13 , 14] . Ethical approval was not required. A system-
tic literature search was performed by an experienced Cochrane
ibrarian in the electronic bibliographic databases MEDLINE, EM-
ASE and CENTRAL from inception to 1st October 2019. The full
earch strategy is presented in the supplementary methods. Stud-
es were identiﬁed by two independent reviewers (SB, AM) and
iscrepancies resolved by a third author (IK). To identify studies
hich might have been missed during the electronic search and
npublished data, we further hand-searched the references of the
rticles in the full-text stage and the proceedings of relevant con-
erences respectively. 
We included all studies examining the degree of HPV DNA
ethylation across the viral epigenome with HPV infection and
ifferent grades of cervical disease as deﬁned by cytology or
istopathology. Any population of women representing a cervical
creening or referral population were included without demo-
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i  graphic restrictions, including retrospective biobanks of samples
for women recruited from such populations and diagnostic accu-
racy studies examining the ability of HPV methylation to diagnose
cytological or histological outcomes, regardless of HPV genotype,
sample material and study methodology. We excluded studies
where a reference standard (cytological and/or histological grade)
was not reported and methylation experiment studies in cell lines
or tumor clones only, due to low applicability to cervical screening
populations. Studies with less than ﬁve participants with CIN2 or
worse were excluded. There was no language restriction. 
2.2. Outcome measures, data extraction and risk of bias 
We explored two primary outcomes. Firstly, we established how
gene-speciﬁc HPV methylation changes with CIN severity. The re-
ported outcome measures presented across studies varied and in-
cluded (a) proportion of samples methylated at a CpG and/or gene
(samples methylated/samples methylated plus samples unmethy-
lated) (b) percentage mean or median methylation at a CpG and/or
gene (0–100% methylation) (c) mean difference (MD) in methyla-
tion (mean methylation in high-grade disease minus mean methy-
lation in low-grade disease) d) odds-ratio (OR) of high-grade vs.
low-grade disease for high methylation (supplementary methods).
Secondly, we determined the diagnostic accuracy of a positive HPV
methylation test (sensitivity, speciﬁcity or area under the curve
(AUC)) in detecting ≥CIN2 and ≥CIN3. 
We assessed the risk of bias for selected studies using a mod-
iﬁed quality assessment tool for diagnostic test accuracy studies
(QUADAS-2) [15 , 16] which covers four main domains: patient se-
lection, index test, reference standard, ﬂow and timing (supple-
mentary methods). We assigned a judgement of low, moderate or
high risk of bias to each of the domains according to the criteria
outlined in QUADAS-2 and the Cochrane Handbook [13] . 
From each included study, two reviewers (SB, AM) extracted
data on study design and setting, index test, sample material, HPV
type, CpG sites analysed, reference standard, outcome measures
and risk of bias using a predeﬁned spreadsheet (supplementary
methods). 
2.3. Statistical analysis 
We analysed methylation changes with disease severity for the
different outcome measures reported across studies; pooled es-
timates of study-speciﬁc means, proportions, MD and OR were
calculated using an inverse variance random-effects meta-analysis
model in the metafor R package v3.6.1. Our main analysis com-
pared two groups based on standardised classiﬁcation systems.
CIN and squamous intraepithelial lesion (SIL) classiﬁcations have
been commonly used to describe cervical disease (cytology and
histology) and the choice has interchanged between different
time periods and continents. Similar grades of disease from ei-
ther terminology were therefore grouped together: women with
≥CIN2/HSIL (histologically conﬁrmed CIN2 or worse/cytologically
deﬁned high-grade squamous intra-epithelial lesion (HSIL) or
worse) vs. ≤CIN1/LSIL (histologically conﬁrmed CIN1 or less/ cyto-
logically deﬁned low-grade squamous intra-epithelial lesion (LSIL)
or less). We used histopathology to determine CIN grade if avail-
able; if histopathology (CIN) was not available or clinically indi-
cated, the cytology result (SIL) was used. Terminology is further
described in the supplementary glossary. 
We compared the proportions of methylated samples for
≥CIN2/HSIL and ≤CIN1/LSIL in a meta-analysis using the variance-
stabilising Freeman–Tukey double arcsine transformation approach.
We used the individual author deﬁnition of methylated samples.
We performed secondary analyses in more deﬁned clinical groups
to include normal, LSIL, HSIL and invasive cervical cancer (ICC). From extracted mean methylation levels we calculated the
tudy-speciﬁc MD. ORs were extracted from studies along with
heir variances, but when these were not available, they were es-
imated from proportions methylated or transformed from contin-
ous data. We performed assessment for publication bias in the
ain analysis by visual assessment of the funnel plot and Egger’s
 -value for small study effects [17] . 
Pooled absolute sensitivity and speciﬁcity were estimated
ointly in a bivariate model using the midas routine in Stata
.14, taking the correlation between true-positive and false-positive
ates and between-study variability into account. Where insuﬃ-
ient data were available, we contacted authors for data by indi-
idual CpG site and varying cut-offs. Pre- and post-test probability
nalyses were calculated using the ppp function [18] . We used the
iagnostic accuracy of the best performing HPV type, gene and CpG
ites. Pre-test probability of CIN2/HSIL or worse in women with
PV16 was estimated from recently presented data [19] . 
We assessed between-study heterogeneity using the Cochran’s
 test, a visual inspection of forest plots, and the I 2 statistic along a
5% conﬁdence interval (CI) [20] . We estimated the between-study
ariance using the restricted maximum likelihood approach in R
nd the DerSimonian and Laird method in Stata. 
We performed predeﬁned sensitivity analyses. For the compar-
son of proportions and mean methylation by disease grade, we
estricted to those that used histopathology alone as a reference
cytology was accepted to deﬁne normal alone). For the MD, OR
nd diagnostic accuracy analyses, we restricted to (a) studies at
ow risk of bias; (b) histopathology as reference test (c) pyrose-
uencing as index test (d) cervical exfoliated cells (CEC) as sam-
le material (e) cut-off limited to 10% mean methylation. In the
D meta-analysis, we additionally excluded imputed SD values for
ensitivity analysis, whereas in the OR meta-analysis, we also ex-
luded the transformed OR values from continuous data and per-
ormed a sub-group analysis by geographical region. 
More details on the methods are described in the supplement
nd in our protocol, which was registered with Open Science
ramework. 
. Results 
The literature search yielded 572 potentially eligible studies; 44
tudies [6–9 , 21–60] and 8819 women were included in the analysis
supplementary table 1, supplementary ﬁgure 1). 
The methodological quality of the studies was overall moder-
te ( Table 1 ). Half were at low-risk of bias, (50 ·0%, 22/44), whilst
he rest had either moderate (45 ·5%, 20/44) or high risk (4 ·7%,
/44). For patient selection, 43 ·2% (19/44) studies scored moderate
o high risk of bias as samples were often selected from biobanks,
ase-controls without consecutive recruitment, with some having
nappropriate exclusions. The index test scored moderate or high
isk of bias in 34 ·1% (15/44); reasons included use of older bisul-
hite sequencing methods, no quantitative measure, and use of
aginal samples. Eighty-six percent (38/44) of studies scored high
r moderate risk of bias on the reference test as there was no
linding of the person performing methylation, while in 13 ·6%
6/44) there was no histological conﬁrmation for high-grade dis-
ase. For ﬂow and timing, there was a delay between methylation
nd reference conﬁrmation in 9 ·0% (4/44) of studies, whilst dif-
erential veriﬁcation bias was present in 50 ·0% (22/44), as studies
witched between cytology and histopathology to conﬁrm disease
rade. 38 ·6% (17/44) of studies explained withdrawals or uninter-
retable results adequately, while 61 ·3% (27/44) were scored un-
lear for insuﬃcient explanation. 
All studies were observational. Forty reported on HPV16, twelve
n HPV18, and twelve on other HPV types. The majority of stud-
es explored the L1 gene ( N = 30), followed by LCR ( N = 29), L2
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Table 1 
Quality assessment for risk of bias for all included studies with tailored QUADAS-2. 
QUADAS-2 domains. P1 = acceptable enrolment method; P2 = acceptable inclusion criteria and inappropriate exclusions avoided; I1 = acceptable sample material (LBC, cervi- 
cal swab, cervical tissue); I2 = Acceptable methylation test giving quantitative results (Pyrosequencing, EpiTYPER, Next generation sequencing, Luminex-C); R1 = Acceptable 
reference test (histology conﬁrmation of grade for CIN and cancer, at least cytology conﬁrmation of grade for normal and ascus); R2 = Masking of methylation analysis to 
reference test; F1 = Acceptable interval between index test and reference standard?; F2 = Differential veriﬁcation avoided; F3 = withdrawals and uninterpretable results 
explained. Subdomains were assessed according to QUADAS-2 guidance by answering yes (green tick), no (red cross) or unclear (yellow exclamation mark), where unclear 
relates to insuﬃcient data for assessment). Domains were assessed by summarising results of subdomains, into high, moderate or low risk of bias. 
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w   N = 15), E6 ( N = 10), E2 ( N = 4), E7 ( N = 3), E5 ( N = 2) and E1
 N = 2). Recent studies used pyrosequencing (27/44, 61 ·3%) and
ext generation sequencing (NGS) techniques (4/44, 9 ·0%) for fur-
her quantiﬁcation. Cut-offs of positivity varied ranging from 0
o 90%, whilst some studies chose dichotomisation after division
y tertiles. Seventeen studies (39 ·5%) reported histopathological
iagnosis for all samples, twenty-two (50 ·0%) histopathology for
CIN2/HSIL and cytology alone for ≤CIN1/LSIL, three studies (7 ·0%)
sed cytology for CIN but histopathology for cancer [26 , 31 , 32] ,
ne study used cytology alone [49] , and two studies did not de-
ne the reference test [33 , 40] . The majority used exfoliated cervi-
al cells (40/44, 90 ·9%). Assessment for publication bias revealed
ome asymmetry with large studies on the left showing a more
onservative estimate, while Egger’s P of < 0 ·01 indicated small
tudy effects (supplementary ﬁgure 2). .1. Methylation and lesion severity 
Within studies reporting proportions of methylated samples ac-
ording to disease grade, we found that rates of positive methy-
ation increased with disease grade. When we compared women
ith ≤CIN1/LSIL to ≥CIN2/HSIL the most marked difference in
he pooled estimates for positive methylation rate were found at
he HPV16 L1 gene (8 studies; pooled positive methylation rate:
CIN1/LSIL = 44 ·4% (95%CI 16 ·0–74 ·1) and ≥CIN2/HSIL = 72 ·7%
95%CI 47 ·8–92 ·2) ( Table 2 ). 
The contrast was consistent for HPV16 L2 gene, although the
umber of studies was smaller and between study heterogeneity
as high (3 studies; 40 ·1% (95%CI 7 ·0–79 ·3) vs. 61 ·8% (95%CI 43 ·9–
8 ·2)), whereas the differences between ≤CIN1/LSIL vs. ≥CIN2/HSIL
ere much smaller at the HPV16 LCR (12 studies; 37 ·5% (95%CI
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Table 2 
Meta-analysis of proportion of HPV methylated samples for different genotypes and genes for ≤CIN1/LSIL vs. ≥CIN2/HSIL. ≤CIN1/LSIL: Nor- 
mal/ASCUS/LSIL/CIN1. ≥CIN2/HSIL: CIN2/CIN3/HSIL/ICC. The grade was deﬁned by histology; if this was not available, cytology was used. 
Author, year Cut-off CpG Study size ≤CIN1/LSIL% (N/N) ≥CIN2/HSIL% (N/N) 
HPV16 L1 % % 
Brentnall 2014 > 0% L1 (bp6367, 6389) 556 90.1 (210/233) 97.8 (326/323) 
Qiu 2015 (1) > 10% L1 (bp5602, 5608, 5611, 5617) 114 40.5 (17/42) 91.6 (66/72) 
Qiu 2015 (2) > 10% L1 (bp7136, 7145) 81 34.3 (11/32) 89.8 (44/49) 
Simanaviciene 2015 > 0% L1 (bp7136, 7145) 157 2.6 (1/39) 24.6 (29/118) 
Gasperov 2015 > 0% L1 (bp7091, 7136, 7145, 7145) 16 30 (3/10) 33.3 (2/6) 
Kalantari 2014 > 0% L1/L2 (bp 5602–7270) 63 13.8 (4/29) 50 (17/34) 
Lorincz 2013 > 0% L1 (bp 6367,6389) 73 100 (48/48) 100 (25/25) 
Wang 2017 > 0% L1 (bp 7089–7268) 100 16.6 (5/30) 50 (35/70) 
Total N – n / N ∗ 1160 299/463 534/697 
Pooled estimate (95% CI) 44.4 (16.0–74.1) 72.7 (47.8–92.2) 
I 2 (95%CI) 97.61 (93.2–99.3) 97.2 (93.3–99.3) 
tau 2 (95%CI) 0.18 (0.07–0.75) 0.11 (0.04–0.41) 
HPV 16 L2 
Brentnall 2014 > 0% L2 (bp4238, 4259, 4275) 556 29.3 (68/233) 55 (178/323) 
Kalantari 2014 > 0% L1/L2 (bp 5602–7270) 63 13.8 (4/29) 50 (17/34) 
Lorincz 2013 > 0% L2 (bp 4238, 4247, 4259, 4268, 4275) 73 79 (38/48) 96 (24/25) 
Total N – n / N 692 110/310 219/382 
Pooled Estimate (95% CI) 40.1 (7–79.3) 61.8 (43.9–78.2) 
I 2 (95%CI) 96.9 (88.1–99.9) 85.2 (39.6–99.7) 
tau 2 (95%CI) 0.12 (0.03–5.12) 0.02 (0.00–1.04) 
HPV16 LCR 
Badal 2003 > 0% 5 ′ LCR, Enh, E6 Prom 81 42.1 (16/38) 9.3 (4/43) 
Bhattarcharjee 2006 > 0% 5 ′ LCR (bp7289-7540) 72 4 (6/15) 54.4 (31/57) 
Ding 2009 > 0% 5 ′ LCR, Enh, E6 Prom (bp7426-58) 53 5.9 (1/17) 41.7 (15/36) 
Dutta 2015 > 0% Enh (bp7535-7694), E6 Prom 215 4.1 (41/93) 44.3 (54/122) 
Hublarova 2009 > 0% E6 Prom (bp7851-7559) 141 81 (17/21) 35.8 (43/120) 
Gasperov 2015 > 0% 3 ′ LCR, Enh, Prom (bp7091-58) 12 50 (3/6) 33.3 (2/6) 
Simanaviciene 2015 > 0% 5 ′ LCR, Enh, Prom (bp7270-58) 157 2.7 (1/39) 23.7 (28/118) 
Xi 2011 > 0% 3 ′ LCR, Enh, Prom (bp7535-58) 211 44.9 (53/117) 35.6 (34/94) 
Snellenberg 2012 > 0% E2BS1 (bp 7370–7383) 65 11.8 (2/17) 64.6 (31/48) 
Hong 2008 > 0% Enh, Prom (bp7676-58) 70 48.4 (15/31) 71.8 (28/39) 
Lorincz 2013 > 0% Prom (bp31-58) 73 90 (43/48) 92 (23/25) 
Wang 2017 > 0% 3 ′ L1, 5 ′ LCR, Enh, Prom (bp7089-58) 101 8.8 (3/34) 32.8 (22/67) 
Total N – n / N 1251 201/476 315/775 
Pooled Estimate (95% CI) 37.5 (20.2–56.5) 44.5 (30.9–58.5) 
I 2 (95%CI) 93.4 (86.4–97.7) 92.8 (85.1–97.6) 
tau 2 (95%CI) 0.09 (0.05–1.04) 0.05 (0.02–0.16) 
HPV 18 L1/L2 
Simanaviciene 2015 > 0% L1 (bp6916-7122) 21 18.2 (2/11) 80 (8/10) 
Gasperov 2015 > 0% L1 (bp7017-7140) 21 100 (9/9) 92.3 (12/13) 
Brentnall 2014 > 0% L2 (bp4256-4282) 201 70.9 (91/128) 84.1 (61/73) 
Kalantari 2014 > 0% L1/L2 (bp5602-7270) 14 14.3 (1/7) 85.7 (6/7) 
Total N – n / N 258 103/155 87/103 
Pooled Estimate (95% CI) 52.6 (13.8–89.8) 86.0 (77.7–92.8) 
I 2 (95%CI) 90.6 (67.7–99.4) 0.0 (0.0–75.4) 
tau 2 (95%CI) 0.14 (0.03–2.30) 0.00 (0.00–0.05) 
HPV18 LCR 
Simanaviciene 2015 > 0% LCR (LCR5 ′ , Prom, Enh) 21 0 (0/13) 20 (2/8) 
Total N – n / N 21 0/13 2/8 
HPV 31 L1/L2 
Brentnall 2014 > 0% L1 (bp6352, 6364) 202 59.6 (62/104) 85.7 (84/98) 
Kalantari 2014 > 0% L1/L2 (bp5518-5692) 15 0 (0/7) 50 (4/8) 
Total N – n / N 217 62/111 88/106 
Pooled Estimate (95% CI) 33.6 (0.0–87.1) 73.7 (34.4–99.3) 
I 2 (95%CI) 89.6 (47.6–100) 89.6 (47.6–100) 
tau 2 0.14 (0.01–100) 0.06 (0–78.5) 
HPV 45 L1/L2 
Kalantari 2014 > 0% L1/L2 (bp4795-7135) 12 0 (0/1) 80 (8/10) 
Total N – n / N 12 0/1 8/10 
HPV 52 L1 
Murakami 2013 > 0% L1 (bp5606-7120) 54 15 (2.6/17) 44.7 (17/37) 
Total N – n / N 54 2.6/17 17/37 
HPV 52 LCR 
Murakami 2013 > 0% LCR (LCR5 ′ , Prom, Enh) 54 2.5 (0.4/17) 2.4 (0.9/37) 
Total N – n / N 54 0.4/17 0.9/37 
( continued on next page ) 
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Table 2 ( continued ) 
Author, year Cut-off CpG Study size ≤CIN1/LSIL% (N/N) ≥CIN2/HSIL% (N/N) 
HPV 58 L1 
Murakami 2013 > 0% L1 (bp5606-7119) 41 12 (2.4/20) 51.1 (10.7/21) 
Total N – n / N 41 2.4/20 10.7/21 
HPV 58 LCR 
Murakami 2013 > 0% LCR (LCR5 ′ , Prom, Enh) 41 0 (0/20) 0 (0/21) 
Total N – n / N 41 0/20 0/21 
ASCUS: abnormal squamous cells of undetermined signiﬁcance: Bp: base pair; CIN: cervical intraepithelial neoplasia; Enh: enhancer region; HSIL: high- 
grade squamous intraepithelial lesion; LCR: long control region; LSIL: low-grade squamous intraepithelial lesion; N : total number of samples; N : number 
of samples methylated; ICC: invasive cervical cancer Prom: promoter region; Q-test: Cochrane Q test. 
Proportion of samples methylated at a CpG and/or gene was deﬁned as: N methylated/ N methylated + N unmethylated. 
Where studies presented results for multiple CpG sites per gene, the mean result for the gene was meta-analysed. 
Table 3 
Pooled mean methylation levels for HPV16 in ≤CIN1/LSIL vs. ≥CIN2/HSIL and pooled difference in mean methylation (MD). The grade was deﬁned by histology; if this was 
not available, cytology was used. 
Gene Studies 
( N ) 
Pooled mean % 
(95%CI) 
I 2 (95%CI) tau 2 
(95%CI) 
Pooled mean % 
(95%CI) 
I 2 (95%CI) tau 2 
(95%CI) 
Pooled MD % 
(95%CI) 
I 2 (95%CI) tau 2 (95%CI) 
≤CIN1/LSIL ≥CIN2/HSIL 
E1 1 3.9 
(2.1–5.7) 
N/A N/A 14.8 
(9.1–20.4) 
N/A N/A 4.0 
( −1.6–9.6) 
N/A N/A 
E2 4 5.6 
(1.6–9.5) 
89.0 
(60.2–98.8) 
13.7 
(2.6–137) 
14.1 
(5.4–22.8) 
87.9 
(62.6–98.6) 
67.9 
(15.7- 679) 
8.8 
(0.2–17.5) 
88.0 
(61.5–98.7) 
67.5 
(14.7–675) 
E5 1 14.0 
(9.8–18.1) 
N/A N/A 26.6 
(17.7–35.5) 
N/A N/A 12.7 
(2.9–22.4) 
N/A N/A 
E6 3 2.1 
(0.8–3.4) 
72.0 
(5.1–99.2) 
0.9 
(0.0–42.7) 
4.8 
(1.7–7.9) 
57.0 
(0.0–96.9) 
4.3 
(0–100) 
2.5 
(0.5–4.4) 
13.3 
(0.0–96.6) 
0.53 
(0.00–100) 
E7 1 5.9 
(4.0–7.9) 
N/A N/A 13.5 
(9.1–17.8) 
N/A N/A 7.5 
(2.4–2.7) 
N/A N/A 
L1 12 10.8 
(7.4–14.2) 
96.3 
(92.2–98.8) 
32.9 
(14.9–105) 
23.3 
(17.8–28.7) 
96.7 
(93.1–98.8) 
87.3 
(41.1–248) 
11.3 
(6.5–16.1) 
93.0 
(85.0–97.6) 
63.4 
(27.2–196) 
L2 5 9.0 
(4.8–13.2) 
99.4 
(98.2–99.9) 
22.1 
(7.5–186) 
15.4 
(9.3–21.4) 
96.0 
(87.8–99.6) 
6.6 
(3.6–20.3) 
5.6 
(1.8–9.4) 
88.0 
(54.3–98.7) 
14.5 
(2.4–145) 
LCR 7 4.0 
(1.4–6.7) 
96.7 
(91.5–99.3) 
12.1 
(4.5–57.3) 
6.6 
(4.0–9.3) 
94.1 
(85.2–98.8) 
11.5 
(4.1–59.2) 
2.5 
( −0.1–4.8) 
87.3 
(64.4–97.9) 
8.11 
(2.13–54.1) 
CIN: cervical intraepithelial neoplasia; LCR: long control region; LSIL: low grade squamous intraepithelial lesion; HSIL: high grade squamous intraepithelial lesion; Q-test: 
Cochrane Q test. Mean methylation levels in studies were determined by percentage mean or transformed median methylation per group of samples, and averaged by gene 
(0–100% methylation). Mean difference values in studies were calculated by subtracting mean methylation values from low-grade disease samples from high-grade disease 
samples, then average by gene (0–100%). 
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d  0 ·2–56 ·5); vs. 44 ·5% (95%CI 30 ·9–58 ·5)). The differences were also
arked for HPV 18 L1/L2 genes (4 studies; 52 ·6% (95%CI 13 ·8–89 ·8)
s. 86 ·0% (95%CI 77 ·7–92 ·8)) and for HPV31 L1/L2 (2 studies, 33 ·6%
95%CI 0 ·0–87 ·1) vs. 73 ·7% (95%CI 34 ·4–99 ·3)). There were not suf-
cient studies for pooled estimates for other HPV types (45,52,58),
lthough the direction of effect was similar in the individual stud-
es. We further analysed the data in more deﬁned groups of nor-
al, CIN1/LSIL, CIN2-3/HSIL, and invasive cervical cancer (ICC) and
imilar associations were observed (supplementary table 2). The
ensitivity analysis using studies that had histopathology alone as
 reference standard were analysed separately (supplementary ta-
le 3). We found consistent results with reduced heterogeneity and
 more marked difference in the methylated rates for HPV16 L1 in
CIN2 vs. ≤CIN1 (71 ·5% (95%CI 24 ·8–99 ·8) vs. 24 ·1% (95%CI 5 ·3–
0 ·0), suggesting that cytology as a reference may have misclassi-
ed disease. The quantiﬁcation of the difference in mean methyla-
ion levels showed that HPV16 methylation was signiﬁcantly higher
n ≥CIN2/HSIL vs. ≤CIN1/LSIL in individual studies in all genes
 P < 0 ·05) except the LCR ( P = 0 ·169) (supplementary ﬁgure 3a).
he pooled mean methylation levels for HPV16 were lower over-
ll in women with CIN1/LSIL or less when compared to those with
IN2/HSIL or more ( Table 3 ). 
There were insuﬃcient data for pooled analysis of other HPV
ypes but the mean methylation levels for HPV18 L1, HPV18
2, HPV18 LCR, HPV35 L2, HPV45 E2, HPV45 L1, HPV45 L2 and
PV59 L1 were systematically signiﬁcantly lower in women withCIN1/LSIL when compared to those with ≥CIN2/HSIL ( P < 0 ·05)
supplementary ﬁgure 3b). In HPV31 L2, HPV33 L1, HPV33 L2,
PV35 L1, HPV51 L1, HPV51 L2, HPV52 L1, HPV52 L2, HPV58 L1
nd HPV58 L2, mean methylation levels in individual studies were
igher in ≥CIN2/HSIL but did not reach statistical signiﬁcance.
hen restricting to studies using histopathology only as reference,
ooled mean methylation levels also increased by disease grade
CIN1, CIN2, CIN3, ICC) in all HPV16 genomic regions (supplemen-
ary table 4). 
The pooled difference in mean methylation level (MD) was sig-
iﬁcantly higher in ≥CIN2/HSIL when compared to ≤CIN1/LSIL for
he HPV16 L1 gene (11 ·3% (95%CI 6 ·5–16 ·1)) followed by E2 (8 ·8%
95%CI 0 ·2–17 ·5)), E7 (7 ·7% (95%CI 3 ·7–11 ·7)), L2 (5 ·6% (95%CI 1 ·8–
 ·4)) and E6 (2 ·5% (95%CI 0 ·5–4 ·4)) ( Table 2 , supplementary ﬁgure
). In the LCR there was no signiﬁcant difference observed (1 ·6%
95%CI −0 ·3–3 ·4)), while for HPV16 E1 and E5 there was only one
tudy with the same direction of effect. High heterogeneity was
bserved in all MD meta-analyses and was explored with a series
f sensitivity analyses that did not substantially improve hetero-
eneity (supplementary table 5). There were insuﬃcient data for
eta-analysis in other HPV genotypes. 
Data to determine odds ratio (OR) comparing proportion of
ethylated samples or mean methylation for ≥CIN2/HSIL vs.
CIN1/LSIL in HPV16 was available in 21 studies; the study-speciﬁc
Rs for HPV16 L1 ranged from 1 ·2 to 36 ·8. The cut-off used to
eﬁne positive methylation varied between studies (range 0–16%).
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Table 4 
Meta-analysis of HPV16 methylation pooled sensitivity, speciﬁcity and area under the curve (by study deﬁned cut-off) in detecting disease ≥CIN2/HSIL and disease 
≥CIN3/HSIL. 
Gene Studies 
( N ) a 
Threshold (%) Pooled sensitivity 
% (95% CI) 
Pooled speciﬁcity 
% (95% CI) 
Pooled estimated AUC 
(95% CI) 
I 2 (95% CI) tau 2 (95% CI) 
BIVARIATE MODEL 
≥CIN2/HSIL 
All studies 
(L1/L2/E2//E5/E6/E7/LCR) 
11 0.4–15.9/3rd tertile 75 (59–86) 65 (57–73) 0.73 (0.69–0.76) 95.1 (93–97) 0.76 (0.00–1.89) 
L1/L2/E5 11 0.4–15.9/3rd tertile 76 (63–86) 64 (56–72) 0.73 (0.69–0.77) 95.0 (93–97) 0.43 (0.00–1.10) 
L1/L2 10 0.4–15.9/3rd tertile 77 (63–87) 64 (55–71) 0.73 (0.69–0.76) 95.5 (94–97) 0.00 (0.00–1.34) 
L1 10 0.4–15.9/3rd tertile 82 (73–88) 57 (49–65) 0.73 (0.69–0.77) 85.9 (78–93) 0.00 (0.00–2.99) 
L2 5 0.4–15.9/3rd tertile 75 (63–84) 66 (42–84) 0.77 (0.73–0.81) 32.9 (0–98) 0.00 (0.00–100) 
L1 6367 5 3.1–10/3rd tertile 74 (64–82) 53 (41–66) 0.70 (0.66–0.74) 73.0 (48–98) 0.35(0.00–0.98) 
L1 6389 5 3.1–10/3rd tertile 77 (67–84) 52 (38–65) 0.71 (0.67–0.75) 67.9 (38–98) 0.00 (0.00–1.64) 
UNIVARIATE MODEL 
≥CIN2/HSIL 
All studies 
(L1/L2/E2//E5/E6/E7/LCR) 
14 0.4–15.9/3rd tertile 74 (60–84) 65 (54–75) 0.782 (0.669–0.864) 39.5 (0–67) 0.50 (0.00–1.58) 
L1/L2/E5 14 0.4–15.9/3rd tertile 75 (62–84) 64 (54–74) 0.810 (0.712–0.880) 37.4 (0–61.7) 0.46(0.00–1.24) 
L1/L2 13 0.4–15.9/3rd tertile 75 (61–85) 64 (53–74) 0.808 (0.685–0.891) 39.7 (0.00–67.14) 0.49 (0.00–1.49) 
L1 13 0.4–15.9/3rd tertile 81 (73–87) 55 (44–66) 0.808 (0.685–0.891) 0.00 (0.00–70.7) 0.00 (0.00–2.62) 
L2 5 0.4–15.9/3rd tertile 81 (69–89) 69 (46–85) – 0.00 (0.00–100) 0.00 (0.00–100) 
LCR 3 0/3rd tertile 45.3 (19–73.4) 75.2(47.6–91.0) – 0.00 (0.00–100) 0.00 (0.00–100) 
LCR/L1/L2 3 5.3/3rd tertile 54.6 (26.1–80.4) 74.2 (45.8–90.7 – 0.00 (0.00–100) 0.00 (0.00–100) 
L1 6367 5 3.1–10/3rd tertile 75 (62–85) 52 (37–67) 0.720 (0.665–0.769) 89.9 (68–99) 0.00 (0.00–1.45) 
L1 6389 5 3.1–10/3rd tertile 82 (68–91) 48 (33–63) 0.834 (0.691–0.918) 98.9 (97–100) 0.18 90.00–6.58) 
L1 5611 3 10.8/3rd tertile – – 0.830 (0.739–0.894) 96.4 (87–100) 0.22(0.05–9.24) 
L1 6650 3 10.8/3rd tertile – – 0.779 (0.653–0.868) 97.8 (92–100) 0.30 (0.08–12.06) 
L1 7145 5 10.8/3rd tertile – – 0.729 (0.649–0.796) 95.6 (88–100) 0.17 (0.06—1.55) 
≥CIN3/HSIL 
L1 7 3.1–15.9 76 (66–84) 75 (57–87) 0.903 (0.804–0.955) 0.00 (0.00–58.6) 0.00 (0.00–0.77) 
CIN: cervical intraepithelial neoplasia; WGA: Whole Genome Average. 
Bivariate models applied wherever possible in preference. When not possible, univariate model were applied. 
a Number of studies and heterogeneity refers to pooled sensitivity meta-analyses, on occasion the number of studies for AUC meta-analyses was less due to less available 
data. 
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w  The pooled point estimate OR was greatest for the HPV16 L1 gene
(22 studies, OR 5 ·5 (95%CI 3 ·5–8 ·5, P < 0 ·0 0 01)) followed by L2
(7 studies, OR 4 ·2 (95%CI 2 ·2–7 ·8, P = 0 ·0 0 01)), E2 (4 studies, OR
2 ·6 (95%CI 1 ·1–6 ·0, P = 0 ·0266)) and E6 (4 studies, OR 2 ·1 (95%CI
1 ·4–3 ·2, P = 0 ·0 0 02)) ( Fig. 1 , supplementary Table 7). The OR was
not signiﬁcantly different from unity for the HPV16 LCR region
( P = 0 ·0682), with a few studies showing signiﬁcant negative as-
sociations. When restricting the analysis to studies reporting only
on proportions, the OR for HPV16 L1 gene was even higher (OR 6 ·5
(95%CI 3 ·8–10 ·9, P < 0 ·0 0 01). Restriction to studies with low risk of
bias, histopathology only, or CEC only, all reduced observed hetero-
geneity. Restriction to pyrosequencing techniques only did not. The
pooled OR for HPV18 L1/L2 was similar (7 studies, OR 8 ·3 (95%CI
2 ·9–23 ·5, P < 0 ·001)). Fewer studies were available for other HPV
types for the L1 gene alone. Subgroup analysis by geographical lo-
cation was applied and revealed no signiﬁcant difference in pooled
estimates of OR according continent, including Americas, East Asia,
Europe and South Asia (supplementary ﬁgure 5). 
3.2. Diagnostic accuracy in detecting high-grade CIN in women 
positive for individual high-risk HPV subtypes 
We calculated sensitivity and speciﬁcity of positive methyla-
tion (as deﬁned by authors) in detecting CIN2 or worse and
CIN3 or worse by pooling estimates by gene and by best per-
forming CpG site. The cut-off for positive methylation varied
across studies (0–15 ·9% or 3rd tertile). The highest sensitivity
and speciﬁcity in CIN2 + detection in HPV16 positive women was
observed by combination of positive methylation across CpG sites
in the HPV16 L1/L2 genes (10 studies, sensitivity 77% (95%CI 63–
87), speciﬁcity 64% (95%CI 55–71), AUC = 0 ·73 (95%CI 69–76),
I 2 = 96%) ( Table 4 and Fig. 2 ). When all HPV genes were includedL1/L2/E2/E5/E6/E7/LCR) the results were similar (sensitivity 75%
95%CI 59–86), speciﬁcity 65% (95%CI 57–73). The pooled estimates
or the L1 gene alone had improved sensitivity (82% (95%CI 73–88))
ith a slight drop in speciﬁcity (57% (95%CI 49–65)). The analy-
is of L2 alone was similar to that of L1/L2 combined (5 studies).
here were suﬃcient data to analyse pooled sensitivity and speci-
city of two single CpG site markers (L16367 and L16389) – perfor-
ance was less than combined gene markers ( Table 4 ). For predic-
ion of CIN3 or worse, sensitivity was similar (76% (95%CI 66–84)),
hile speciﬁcity (75% (95%CI 57–87)) and AUC (0 ·90 (95%CI 0 ·80–
 ·96)) were greater (supplementary ﬁgure 9). 
Restriction to studies at low risk of bias in the analyses of
he HPV16 L1/L2 gene reduced heterogeneity ( I 2 = 81%); sensitiv-
ty was improved (80%) with no change in speciﬁcity (63%). Simi-
arly, restriction to histopathology only studies increased sensitivity
o 80 ·5%, while other analyses (including restriction to a 10% cut-
ff and pyrosequencing only techniques) did not change estimates
supplementary ﬁgures 13–17). 
We also performed meta-analysis of AUC for CpG sites L15611,
16367, L16389, L16650 and L17145, for detection of CIN2 + and of
1 5611 for CIN3 + . The greatest pooled estimated AUC for CIN2 +
as observed at L16389 (0 ·83 (95%CI 0 ·69–0 ·92)) and L15611 (0 ·83
95%CI 0 ·74–0 ·89)) ( Table 4 ). Where meta-analysis of AUC was not
ossible, we plotted AUC values for diagnostic accuracy of methyla-
ion in predicting CIN2 + and observed a clustering of higher values
n L1/L2 regions when compared to LCR (supplementary ﬁgure 18).
his was similar for HPV18, 31, 33, 45 and 52, whilst for HPV31,
he E1/E2 had greater AUC than the L1 gene (supplementary ﬁgure
9). 
We further compared the pre-test and post-test risk of CIN2 or
orse and CIN3 or worse in a HPV16 positive screening population
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Fig. 1. Meta-analysis of odds ratios of HPV16 methylation in genes L1, L2, LCR, E2, E6 for ≤CIN1/LSIL vs. ≥CIN2/HSIL. 
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r   Fig. 3 ). Using the highest performing genes and sites (pooled sen-
itivity 77% – speciﬁcity 64%), a positive methylation test increased
he risk of CIN2 or worse from 23 ·0% to 39 ·0%, whilst a negative
est result decreased the risk to 9 ·7%. Risk of CIN3 or worse in a
PV16 + woman with a positive methylation test rose from 16 ·0%
o 35 ·8% whilst a negative test result decreased risk to 5 ·8%. 
. Discussion 
.1. Main results in context with published literature 
We observed that the proportion of positive methylation
nd mean methylation levels increased with disease severityredominantly in L1 and L2 regions, but also in the E2 and E6
enes, while no correlation was present in the HPV16 LCR pro-
oter/enhancer region. Pooled differences in the mean methyla-
ion levels and odds ratios for high methylation in ≥CIN2/HSIL vs.
CIN1/LSIL were greatest for HPV16 L1 gene followed by the L2.
PV16 L1/L2 genes had overall the best diagnostic accuracy in de-
ecting CIN2 or worse. When applied in a pre- and post-test proba-
ility model with a 23% risk of CIN2 in HPV16 positive women, the
isk of CIN2 or worse increased to 39% if methylation positive and
ecreased to 10%, if negative. Half of studies had moderate to high
isk of bias according to QUADAS-2 criteria for diagnostic test accu-
acy. The heterogeneity was overall high for most analyses. We per-
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Fig. 2. Diagnostic accuracy of HPV16 L1/L2 in predicting CIN2/HSIL or worse (bivariate model) (a) Pooled sensitivity and speciﬁcity (b) SROC curve. 
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e  formed a series of sensitivity analyses to explore possible causes of
heterogeneity however, residual heterogeneity remained high. 
The published literature to date on HPV methylation in cer-
vical disease has explored various HPV types, genes and adja-
cent CpG sites with conﬂicting results. The majority of studies
explore HPV16 and consistently reports higher methylation levels
with increasing disease severity for L1/L2, in line with our pooledesults. Although human DNA methylation of promoter/enhancer
egions have been previously associated with increased tumori-
enesis in other cancers [61] , the HPV LCR region revealed no
orrelation with disease severity in our analysis. The evidence
n individual studies has been conﬂicting, with 15 studies re-
orting higher methylation in the LCR region in high-grade dis-
ase, while 6 studies observed lower methylation [37 , 49–51] . The
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Fig. 3. Pre- and post-test probability of HPV16 methylation testing for detection of (a) ≥CIN2 and (b) ≥CIN3 in HPV 16 positive women of a screening population. Colours 
represent clinical recommendations for degree of risk requiring referral to colposcopy where red = high risk, yellow = moderate risk and green = low risk. Pre-test probability 
of CIN2 + or CIN3 + estimated from a HPV16 + screening population PPV of CIN2 + or CIN3 + . 
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H  iological processes leading to variation in HPV CpG site perfor-
ance are not well understood. The L1 and L2 genes code for
ate viral capsid proteins, particularly important for viral transmis-
ion during the early stages of infection. Possibly these genes are
ubsequently silenced, allowing prioritisation of E6/E7 oncogene
xpression for carcinogenesis [62] . Studies examining the wholePV genome have so far been limited but suggest a global increase
n methylation by disease grade except for the LCR [6 , 41] . As se-
uencing costs decrease, whole genome methylation analysis could
rove of great beneﬁt in determining CpG sites of best discrimina-
ion, avoiding bias and improving understanding of the variation in
PV methylation across the genome. Downstream functional stud-
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f  ies would also be helpful for further mechanistic understanding of
the role of HPV methylation in cervical precancer progression. 
The detection of women at high risk of CIN2 or worse has
been a great challenge for population-based screening. The in-
troduction of the hrHPV DNA test in screening offers improved
protection against invasive cervical cancer when compared with
cytology [3] and is expected to replace cytology globally. HPV
testing will inevitably increase the number of women that test
positive at screening, while the optimal triage test to accurately
select those warranting colposcopy remains unclear. Optimising
detection, while minimising over-intervention in women at low
risk, has major beneﬁts. In many countries like the UK, reﬂex cytol-
ogy will be used due to ease and existing infrastructure, although
its sensitivity in the detection of CIN3 or worse, is at best 53–75%
with a speciﬁcity of 78–86% [63–65] . Further molecular markers
have been proposed to improve the speciﬁcity and NPV, although
evidence on superiority of any one of these is lacking. P16/Ki-67
immunostaining appears to improve speciﬁcity but requires cytol-
ogy reporting and highly-trained staff with additional costs [66] .
HPV genotyping has also been suggested to increase speciﬁcity
(70–71%) [67] , with the advantage of a streamlined, automated
HPV workﬂow and potential for self-sampling, but suffers from the
inability to distinguish between transient and persistent viral in-
fection and therefore has a low PPV (13–29%), that is likely to fall
further with the drop of HPV prevalence in vaccinated cohorts [68] .
HPV mRNA tests compare well to HPV genotyping assays, with a
high sensitivity but no apparent increase in speciﬁcity [69] while
E6/E7 protein assays have low sensitivity but may improve speci-
ﬁcity over HPV genotyping and cytology [70] . 
The diagnostic accuracy of HPV16 L1/L2 methylation in the de-
tection of CIN2 or worse compares well to other proposed triage
markers (sensitivity = 77%, speciﬁcity = 64%, AUC = 0 ·73) with
the highest pooled AUC for a single CpG site at HPV16 L16389
(0 ·83). HPV methylation has several practical advantages given that
analysis can be streamlined in the same pipeline with that of
hrHPV testing, allowing for future automation and potentially self-
sampling. HPV methylation also performed well compared to host
methylation for the detection of CIN2 or worse (sensitivity = 69–
74%; speciﬁcity = 66–76%) [11] . 
There were suﬃcient data to meta-analyse sensitivity and
speciﬁcity for two individual HPV16 CpG sites which performed
well compared to combined markers. We were further able to
perform pooled analysis for AUC values for 5 HPV16 CpG sites.
We found the greatest AUC at L15611 and L16389 (0 ·83), out-
performing AUC pooled estimates for all other combined markers
including L1/L2 and individual genes L1 and L2. Pooled AUC
estimates for L15611 and 6389 are also greater than the best
performing estimates published for combined host and viral
methylation markers for detection of CIN2 or worse in UK screen-
ing populations (AUC = 0 ·78, sensitivity = 74% (95%CI 59–85),
speciﬁcity = 65% (95%CI 60–70%)) [43] . Continued genome-wide
exploration of HPV genotypes should determine the most accu-
rate CpG sites alone or in combination that will yield greater dis-
crimination. Next-generation sequencing methylation assays could
allow for accurate whole genome coverage, while also improv-
ing consistency of methylation testing. Eventual HPV methylation
tests however should be targeted to sequencing the best per-
forming CpG sites which will facilitate low-cost, high-throughput
automation. 
To date cervical screening targeted the detection of high-grade
pre-invasive disease. Modern molecular markers have the poten-
tial to advance this beyond the current status quo and provide
information on the true carcinogenic potential of hrHPV infec-
tions irrespective of histological disease grade, allowing predic-
tion of women that are likely to have progressive or regres-
sive infection and/or disease [71] . As local cervical treatment in-reases reproductive morbidity, ability to avoid unnecessary treat-
ents has major beneﬁts [72] . Several studies explored the value
f methylation in predicting HPV persistence or development of
igh-grade CIN. One of the largest longitudinal cohorts from Gua-
acaste, Costa Rica [7] , demonstrated that high methylation in
1/L2 of 72 pre-diagnostic specimens was associated with in-
reased risk of future CIN2 + , with an OR of up to 9 ·3 (95%CI 2 ·3–
5 ·1). Niyazi et al. [48] found similar results for L1 methylation in
45 women infected with HPV16, with an OR of up to 9 ·9 (95%CI
 ·6–27 ·4). Longitudinal data could not be meta-analysed in our
tudy. 
.2. Strengths and limitations 
This is the ﬁrst systematic review and meta-analysis to ap-
raise all published literature exploring the use of HPV methyla-
ion in cervical disease. We included 44 studies and over 8819
rHPV positive women and explored data for all HPV subtypes,
enes and CpG sites (including previously unpublished data) and
rovide a robust quality assessment of this literature. We per-
ormed meta-analytical pooling for a number of outcomes, in-
luding measures of positive methylation rate and mean methy-
ation according to disease severity, along with odd ratios and di-
gnostic accuracy meta-analyses to determine test accuracy in de-
ecting high-grade CIN in HPV positive women. To this end we
ave brought together a complex body of literature and present
ooled estimates of methylation data by genotype, gene and CpG
ite, with corresponding risk of bias and heterogeneity assess-
ents. We further calculated the pre- and post-test probability
f high-grade CIN, providing a translational and understandable
ool for policy makers, clinicians and patients to inform about
isk. 
There were however some limitations. Half of the studies were
t moderate or high risk of bias and there was substantial het-
rogeneity for most analyses. The included studies used different
ligibility criteria, sequencing tests, sampling techniques, and ref-
rence veriﬁcation standards; many did not adhere to diagnostic
est accuracy study principles including unbiased patient selection,
nvestigator blinding to the reference test or avoidance of differ-
ntial veriﬁcation bias [13] . We performed a series of sensitivity
nalyses to explore heterogeneity. Restricting to studies at low risk
f bias, or using histopathology for veriﬁcation, or exfoliative cells
nly, reduced heterogeneity in analyses of mean methylation and
Rs ( ≥CIN2/HSIL vs. ≤CIN1/LSIL). Restricting to pyrosequencing
nd NGS alone, did not. To further assess whether the transforma-
ion of median to means and imputation of SD values introduced
ias, we performed sensitivity analysis to exclude imputed values,
ith a similar direction of effect observed. Most studies explored
1 and L2 genes that increased statistical power for these com-
arisons, and repeat assessment of selected CpG sites could have
ed to conﬁrmation bias. Overall there appears to be a clear asso-
iation between increasing HPV methylation with cervical disease
rade, however large variation in effect sizes exists and residual
eterogeneity is yet to be fully explained. The heterogeneity was
verall high for most analyses. Although heterogeneity is known to
e higher in meta-analyses of continuous rather than those of bi-
ary data [73] there are very likely other underlying reasons for
he observed large heterogeneity. Methylation testing is still under
evelopment and not fully standardised. Furthermore, only a few
tudies assessed reproducibility by duplicate and triplicate analysis
f experimental test results. Different studies have used different
ethylation techniques and reference standards. There was insuf-
cient evidence to evaluate whether environmental factors, such
s smoking [74] , modiﬁes HPV methylation levels to cause het-
rogeneity; this would be an important research direction for the
uture. Additionally, small study effects were found to be present
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dhere investigated (Egger’s P < 0.01) and although overall we
ould not formally test all analyses, similar bias of smaller stud-
es showing more extreme estimates might still be present and ex-
lain some of the interstudy heterogeneity. We now need larger
tudies and a collaborative approach, which uses a standardised
ethodological approach and cut-off, in order to accurately deter-
ine the strength of this association. 
The substantial heterogeneity noted in the diagnostic test ac-
uracy (DTA) analyses did not improve when restricting to good
uality studies. This is likely due to studies using different cut-
ff points for positivity and exploring various CpG sites, resultantly
ooled point estimates should be interpreted with caution. In our
nalysis, we aimed to explore this: where more than one cut-off
as provided, we used the most overlapping cut-off thresholds be-
ween studies and performed a sensitivity analysis restricting to
tudies using 10% mean methylation as a cut-off. We used aver-
ges of CpG sites by gene but also analysed separately studies pre-
enting single CpG sites where data were suﬃcient. The overall
ensitivity and speciﬁcity did not differ greatly in either analysis,
lthough AUC values for single CpG sites performed better than
ombined gene averages. Sensitivity analyses were small, and it is
ikely there was not suﬃcient power to adequately detect cut-off
nd CpG effects. Although not previously discussed, methylation
classiﬁers’ have attempted to bring the best performing CpG sites
o a single marker and are currently under validation [43] . Future
esearch should assess whether weighted combination of several
est performing CpG sites has the potential to further improve the
iagnostic accuracy. Following this it will be crucial to determine
he best cut-off for an eventual diagnostic test, which our review
uggests may vary according to the included CpG sites. It should
e noted that a cut-off of 0% should not be used, to avoid confu-
ion with failed assays. Once cut-offs and CpG sites have been es-
ablished, robust and blinded diagnostic test accuracy studies are
eeded to reduce risk of bias in methylation studies and deter-
ine the true chances of false positives and negatives, including
n including in populations of different geographical regions and
thnicities. 
Despite these limitations, this meta-analysis provides the most
omprehensive review and critical appraisal of the existing litera-
ure with stringent quality assessment of the methodological va-
idity of existing studies; this information on the best performing
echniques, cut-offs, genes and CPG sites should inform future de-
ign of diagnostic accuracy studies, including standardisation of as-
ays. For translation to clinical practise we urgently need larger
nd higher quality evidence. To provide this, a collaborative and
tandardised research approach, with consideration of data deposi-
ion on publicly available repositories, should be encouraged in the
eld. 
We calculated pre- and post-test probabilities based on the
ates of high-grade CIN in HPV16 positive women irrespective
f cytology as an example of a screening population. We used
he best performing sites and genes (HPV16 L1/L2) and saw that
ethylation added good additional discrimination between high
nd low-grade disease, although pre-test probabilities of HPV16
ositive women were high. Multiplexed methylation assays com-
ining CpGs across all hrHPV types are currently under develop-
ent [75] , while multiplexing for HPV genotyping is becoming
ell established [76] . To increase the clinical utility of viral methy-
ation testing, multiplexed methylation assays are needed to cover
ll hrHPV types and could be applied to triage women screening
s hrHPV positive, who have not been genotyped. In this scenario,
re-test probabilities would be lower [18] and the value of methy-
ation testing would increase. Our estimates represent the most ac-
urate and conservative estimate of how future multiplexed assays,
ncluding all HPV genotypes, could perform for triage of hrHPV
ositive women. . Conclusions 
This study provides the most comprehensive summary of how
ifferent HPV methylation CpGs, genes and combinations perform.
e demonstrated that HPV methylation correlates with disease
everity and calculated the diagnostic accuracy of methylation for
ndividual HPV genotypes in detecting high-grade CIN in HPV posi-
ive women. These results demonstrate that viral methylation may
e a useful epigenetic marker for cervical cancer prevention. It
s anticipated that technical improvements and standardisation of
rotocols will further increase clinical accuracy of epigenetic mark-
rs. One of the major challenges is that viral methylation is type-
peciﬁc and future tests should allow for a multitude of markers,
argeting all hrHPV types, in one assay. Cut-offs need to be estab-
ished and comparison of the performance of viral to host methyla-
ion will be needed, whilst their combination may further enhance
ccuracy. 
Next-generation multiplex sequencing assays containing all HPV
enotypes are under development and have the potential to allow
apid, automated and low-cost methylation testing. With the as-
umption that these will perform at least as well as the pooled
iagnostic accuracy for HPV16 L1/L2, viral methylation has the po-
ential to evolve to a useful candidate triage marker in women that
est positive of hrHPV at primary screening, determining who will
arrant further colposcopy. When such assays become available,
arge high-quality clinical trials in screening populations compar-
ng various triage tools head-to head will be needed. 
Our study provides important evidence that can inform future
esearch directions and can enhance our understanding of the im-
act of epigenetic changes of the host and the virus in cervical
isease and introduction of new molecular technologies to clini-
al practice. Future studies should explore epigenome-wide associ-
tions in the host, should validate reproducibility of high-quality
ultiplex assays for all HPV types, followed by clinical trials in
creening populations. Exploration of methylation in longitudinal
ohorts has the potential to also enlighten its possible predictive
alue in disease progression. 
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